Contingent Value Rights: Purpose: CVRs are use
Post# of 153897
(Total Views: 482)
Posted On: 06/03/2025 11:53:13 AM
Re: Evil Rabbit #153811
Contingent Value Rights:
Purpose:
CVRs are used to bridge valuation gaps in mergers and acquisitions, particularly when there's uncertainty about the future value of a company or its assets.
Triggers:
CVRs are typically tied to specific events like achieving regulatory approval, hitting sales targets, or reaching certain financial milestones.
Payout:
If the event occurs, the CVR holder receives a predetermined payout, often in cash.
(from Google AI)
Would be a great question for the annual meeting or other public forum--
Are you looking at a CVR to safeguard shareholder value in the event of buyout negotiations?
Structured per indication, based on the successful completion of Phase II trials... Or some other likely-to-reach, near-term milestone.
And only after Cytodyn reaches an understanding on the developmental path forward for leronlimab, getting it to patients rapidly and getting fair value for shareholders...
(Note--given their history, this would exempt Gilead from consideration, because "fair value" is not how they operate (!)).
In this scenario--anyone except Gilead--I would take the CVR in shares of the acquiring company. The buyout preferably in dollars or euros...
Get crackin' Mr Robert Hoffman... You've got some substantial work on the table for the next few months!
Purpose:
CVRs are used to bridge valuation gaps in mergers and acquisitions, particularly when there's uncertainty about the future value of a company or its assets.
Triggers:
CVRs are typically tied to specific events like achieving regulatory approval, hitting sales targets, or reaching certain financial milestones.
Payout:
If the event occurs, the CVR holder receives a predetermined payout, often in cash.
(from Google AI)
Would be a great question for the annual meeting or other public forum--
Are you looking at a CVR to safeguard shareholder value in the event of buyout negotiations?
Structured per indication, based on the successful completion of Phase II trials... Or some other likely-to-reach, near-term milestone.
And only after Cytodyn reaches an understanding on the developmental path forward for leronlimab, getting it to patients rapidly and getting fair value for shareholders...
(Note--given their history, this would exempt Gilead from consideration, because "fair value" is not how they operate (!)).
In this scenario--anyone except Gilead--I would take the CVR in shares of the acquiring company. The buyout preferably in dollars or euros...
Get crackin' Mr Robert Hoffman... You've got some substantial work on the table for the next few months!
(8)
(0)